Skip to main content
Main navigation - Mobile
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Amgen prices bone drug Evenity on par with rival Tymlos
Tuesday, April 16, 2019
Evenity's annual price of $21,900 is on par with that of Radius' rival med Tymlos. But its safety and clinical efficacy profile might hurt uptake.
Amgen bone drug Evenity wins FDA nod, but with strings attached
Wednesday, April 10, 2019
On its second try, Evenity won approval only in postmenopausal women at high risk of bone fracture—and with a boxed warning.
Court tosses kickbacks case against Eli Lilly
Wednesday, August 15, 2018
Whistleblowers alleging Lilly ran a "multi-tiered kickback scheme" will have to rework their complaint after a judge tossed the case.
Lilly CEO to pharma: Stop talking and get going on pricing
Wednesday, January 10, 2018
Merck & Co.'s top executive said Monday that pricing pressure isn't likely to get worse. But Eli Lilly CEO David Ricks begs to differ.
Lawsuit claims Lilly used free nursing to boost insulin sales
Thursday, November 16, 2017
Eli Lilly faces allegations it ran a "multi-tiered kickback scheme" to pump up sales of key diabetes drugs.
CVS formulary knocks Jardiance in favor of Invokana
Wednesday, August 2, 2017
Right on the heels of Express Scripts’ 2018 formulary release, rival PBM giant CVS Caremark has published its list of which drugs are in and which are out.
Radius bone drug catches a break as Express Scripts boots Forteo
Tuesday, August 1, 2017
Analysts expected Eli Lilly’s Forteo to be the big challenge standing in the way of new Radius bone drug Tymlos. But Express Scripts apparently has other ideas.
Express Scripts formulary knocks Lilly, Amgen meds—plus 62 more
Monday, July 31, 2017
Several exclusions in Express Scripts' new formulary, or a lack thereof in some fields, highlight trends in the drug business.
Amgen drug's red flag could spur its Radius rival
Monday, May 22, 2017
Amgen says it’ll be a while before its bone drug romosozumab can fight Radius' Tymlos for market share—if it can get it there at all.